恶性疟原虫对青蒿素产生抗性的研究进展  

Research Progress on Artemisinin Resistance in Plasmodium falciparum

作　　者：张逸龙[1] 潘卫庆[1] 

机构地区：[1]第二军医大学热带传染病学教研室,上海200433

出　　处：《中国寄生虫学与寄生虫病杂志》2015年第6期418-424,共7页Chinese Journal of Parasitology and Parasitic Diseases

摘　　要：青蒿素及其衍生物是我国发明的强效抗疟药,WHO已推荐以青蒿素为基础的联合用药(ACTs)为治疗恶性疟的一线药物。青蒿素及其衍生物的应用已使全球疟疾流行得到了有效控制,疟疾发病率和死亡率逐年下降。但近年来,在东南亚多个地区陆续报道恶性疟原虫(Plasmodium falciparum)对青蒿素类药物产生抗性,并有进一步扩散的趋势,这已严重威胁到全球疟疾防治和消除疟疾计划的实施。本文综述近年来恶性疟原虫对青蒿素产生抗性研究领域的相关研究进展,包括青蒿素抗药性的检测方法、抗性相关的分子标记、抗性虫株的起源及传播流行等。Artemisinin （ART） is a novel and effective antimalarial drug discovered in China. As recommended by the World Health Organization, the ART-based combination therapies （ACTs） have become the first- line drugs for the treatment of falciparum malaria. ART and its derivatives have contributed greatly to the effective control of malaria globally, leading to yearly decrease of malaria morbidity and mortality. However, there have recently been several reports on the resistance of Plasmodium falciparum to ART in Southeast Asia. This is deemed a serious threat to the global malaria control programs. In this paper, we reviewed recent research progress on ART resistance to P. falciparum, including new tools for resistance measurement, resistance-associated molecular markers, and the origin and spread of the ART-resistant parasite strains.

关 键 词：青蒿素 恶性疟原虫 抗药性 起源 

分 类 号：R382.312[医药卫生—医学寄生虫学]